Horizon Discovery Appoints Richard Vellacott as Chief Financial Officer

31 Jul 2012

Cambridge, UK, 30 July 2012: Horizon Discovery Limited (“Horizon”), a leading provider of research tools to support the development of personalized medicines, has announced the appointment of Mr. Richard Vellacott as Chief Financial Officer.

Richard has over 15 years’ experience in working with life science companies, from start-ups to global pharmaceuticals, and is a chartered accountant with a first class degree in Biological Sciences from the University of Durham. Prior to joining Horizon, Richard was Vice President, Finance at CSR plc, a listed hi-tech company with revenues of $1bn. During his time at CSR, Richard had worldwide responsibility for finance, making significant contributions to the transformational acquisition and integration of NASDAQ listed Zoran Corp., product portfolio management, R&D budgeting and business investment / divestment decisions. Before this, Richard was a Director in Deloitte’s life sciences practice, where he specialized in capital market transactions including IPOs, M&A and fundraising on both the UK and the US markets.

Dr. Darrin Disley, CEO of Horizon, commented: “I’m delighted to welcome Richard to Horizon. As the company continues to expand, it is essential that we maintain a highly experienced executive team with the skills to deliver our growth objectives. Richard’s background is an ideal fit and I very much look forward to working with him.”

Richard commented: “I am extremely pleased to join Horizon at a time of significant opportunity for the company. I look forward to working with a highly talented team of people, to create value and deliver on our strategic ambitions.”